LakeShore Biopharma Co LtdNASDAQ:LSB
- LAST PRICE2.6900
- TODAY'S CHANGE (%)0.0700 (2.6718%)
- Bid / Lots2.5400/ 1
- Ask / Lots2.6900/ 5
- Open / Previous Close2.6200 / 2.6200
- Day Range
- 52 Week Range
- Volume3,851
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LSB |
|---|---|---|
| 10:56 ET | 150 | 2.62 |
| 12:12 ET | 100 | 2.55 |
| 12:39 ET | 1602 | 2.5864 |
| 01:36 ET | 300 | 2.69 |
Nov 7, 2024
LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 29, 2024
*DJ LakeShore Biopharma Regains Compliance With Nasdaq Minimum Bid Price Requirement, from 8:31AM ET on Tuesday Oct 29, 2024 by Dow Jones
8:31AM ET on Tuesday Oct 29, 2024 by Dow JonesLakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement, from 8:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
8:30AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LakeShore Biopharma Co Ltd | 50.0M | -0.5x | --- |
Medicure Inc | 6.7M | -3.7x | --- |
Syros Pharmaceuticals Inc | 7.9M | -0.1x | --- |
BioNexus Gene Lab Corp | 5.2M | -6.3x | --- |
Immunoprecise Antibodies Ltd | 10.8M | -0.5x | --- |
Jaguar Health Inc | 9.6M | -0.1x | --- |
Company Information
LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Contact Information
Executives
- Chairman of the Board
- Yi Zhang
- President, Co-Chief Executive Officer, Director, Chief Business Officer
- Hui Shao
- Interim Co-Chief Executive Officer, Director
- Dave Chenn
- Chief Financial Officer
- Chunyuan Wu
- Head of Marketing and sales
- Gang Li
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $50.0M |
|---|---|
Revenue (TTM) | $79.1M |
Shares Outstanding | 19.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-5.55 |
Book Value | $4.25 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -77.75% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
